Anti-GD2 IgG1 monoclonal antibody that mediates ADCC and complement-dependent cytotoxicity against GD2-positive tumor cells.
Chimeric IgG1 anti-GD2 monoclonal antibody that binds GD2 on tumor cells and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, resulting in lysis of GD2-positive cells.
Binds GD2 on target cells and triggers Fc-mediated ADCC (e.g., NK cells/macrophages) and complement-dependent cytotoxicity, causing lysis of GD2-positive cells.
An intravenous bispecific T-cell engager (BiTE) antibody (AMG 757; IMDELLTRA) that binds DLL3 on SCLC tumor cells and CD3 on T cells, creating an immune synapse to activate TCR/CD3 signaling and redirect T-cell cytotoxicity against DLL3-expressing cells.
Bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells, creating an immune synapse that activates TCR/CD3 signaling and redirects T-cell cytotoxicity to kill DLL3-expressing cells (e.g., SCLC).
Bispecific T-cell engager binds DLL3 on target cells and CD3 on T cells, forming an immune synapse that activates TCR/CD3 signaling and triggers perforin/granzyme-mediated killing of DLL3-expressing cells.
Investigational intravenous immunotherapy evaluated as monotherapy in a first-in-human Phase 1 dose-escalation/expansion trial in metastatic castration-resistant prostate cancer; exact target and mechanism undisclosed.
Dual-targeting antibody–drug conjugate against PSMA and STEAP1. Upon binding these antigens on tumor cells, the complex is internalized and an undisclosed cytotoxic payload is released intracellularly, inducing tumor cell death; the exact payload and cytotoxic mechanism are not disclosed.
An ADC binds PSMA on tumor cells, is internalized, and releases an intracellular cytotoxic payload that kills the cell.
Investigational intravenous immunotherapy evaluated as monotherapy in a first-in-human Phase 1 dose-escalation/expansion trial in metastatic castration-resistant prostate cancer; exact target and mechanism undisclosed.
Dual-targeting antibody–drug conjugate against PSMA and STEAP1. Upon binding these antigens on tumor cells, the complex is internalized and an undisclosed cytotoxic payload is released intracellularly, inducing tumor cell death; the exact payload and cytotoxic mechanism are not disclosed.
As an ADC, ABBV-969 binds STEAP1 on the cell surface, is internalized, and releases an (undisclosed) cytotoxic payload inside the cell, leading to target cell death.
Intravenous bispecific T-cell engager antibody that binds CD123 on AML blasts/leukemia stem cells and CD3 on T cells to redirect cytotoxic killing; priming doses used to mitigate cytokine release syndrome.
Fc-modified bispecific antibody that binds CD123 (IL-3Rα) on AML blasts/leukemia stem cells and CD3 on T cells, crosslinking tumor cells with T cells to activate and expand cytotoxic T lymphocytes and drive perforin/granzyme-mediated lysis of CD123+ cells; Fc domain extends half-life and step-up dosing is used to mitigate cytokine release syndrome.
The bispecific antibody links CD123 on target cells to CD3 on T cells, activating T cells to mediate perforin/granzyme-dependent cytolysis of CD123+ cells.